Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefonicid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.77 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.77 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.77 |
| ▸ | PGR | P06401 | 1/20 | 0.77 |
| ▸ | PPARG | P37231 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.68 |
| ▸ | MAPT | P10636 | 9/20 | 0.68 |
| ▸ | POLB | P06746 | 9/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | APEX1 | P27695 | 1/20 | 0.68 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefonicid SCHEMBL13297839 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL16072827 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL537693 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL9080022 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL18048103 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL28744041 | 0.99 | SLC6A4 (0.99) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL27856008 | 0.99 | SLC6A4 (0.99) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL41894 | 0.99 | SLC6A4 (0.99) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL27865839 | 0.99 | SLC6A4 (0.99) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL8425120 | 0.99 | SLC6A4 (0.99) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11498 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637481-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-05-26 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | RECREO PHARMACEUTICALS LLC (US) | 2025-07-29 | — | — | US | claimed |
| US-20250228841-A1 | COMPOSITIONS AFFECTING PIGMENT PRODUCTION AND METHODS FOR TREATMENT OF BACTERIAL DISEASES | APTORUM THERAPEUTICS LTD (HK) | 2025-07-17 | — | — | US | claimed |
| US-20250222118-A1 | Beta-Lactam-Cannabinoid Conjugate Molecules | DIVERSE BIOTECH INC (US) | 2025-07-10 | — | — | US | claimed |
| US-4729989-A | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts | MERCK & CO., INC. (US) | 1988-03-08 | — | — | US | claimed |
| US-4692441-A | B-LACTAM ANTIBIOTICS | MERCK & CO., INC. (US) | 1987-09-08 | — | — | US | claimed |
| EP-0215697-A2 | Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments | MERCK & CO. INC. (US) | 1987-03-25 | — | — | EP | claimed |
| EP-0214898-A2 | Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities | MERCK & CO. INC. (US) | 1987-03-18 | — | — | EP | claimed |
| EP-0084925-B1 | 6-AMINOALKYLPENICILLANIC ACID 1,1-DIOXIDES AND DERIVATIVES AS BETA-LACTAMASE INHIBITORS | PFIZER INC. (US) | 1986-04-09 | — | — | EP | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
| US-4503040-A | 6-(Aminoacyloxymethyl)penicillanic acid 1,1-dioxides as beta-lactamase inhibitors | PFIZER INC. (US) | 1985-03-05 | — | — | US | claimed |
| US-4452796-A | ANTIBIOTICS | PFIZER INC. (US) | 1984-06-05 | — | — | US | claimed |
| US-4427678-A | 6-Aminomethylpenicillanic acid 1,1-dioxide derivatives as beta-lactamase inhibitors | PFIZER INC. (US) | 1984-01-24 | — | — | US | claimed |
| EP-0084925-A1 | 6-Aminoalkylpenicillanic acid 1,1-dioxides and derivatives as beta-lactamase inhibitors | PFIZER INC. (US) | 1983-08-03 | — | — | EP | claimed |